Key result
Manifest depressive symptoms in ESRD linked to ~230% higher 1-year all-cause mortality.
Why the study?
Do depressive symptoms reduce survival in patients with end-stage renal disease on renal replacement therapy?
Population
101 patients with end-stage renal disease (ESRD) on renal replacement therapy (RRT) in a Dutch cohort
Comparison
Manifest depressive symptoms vs Depressive symptoms below threshold
Design
Cohort
Follow-up
1 year
Authors
Loading...
Depressive symptoms may identify high-risk ESRD patients on RRT; leaves open whether screening or treatment improves survival.
Cohort (n=101)
Do depressive symptoms reduce survival in patients with end-stage renal disease on renal replacement therapy?
Hazard Ratio: 3.3 (95% CI 1.2–9.6)
Absolute Event Rate: 26% vs 8%
p-value: p=0.02
In patients with end-stage renal disease on dialysis, depressive symptoms are highly prevalent and independently associated with increased 1-year mortality, primarily driven by a higher incidence of septicaemia.
Riezebos et al. (2009) conducted a cohort in End-stage renal disease (ESRD) (n=101). Depressive symptoms (HADS-D score ≥7) vs. Depressive symptoms below threshold (HADS-D score <7) was evaluated on All-cause mortality (HR 3.3, 95% CI 1.2-9.6, p=0.02). Manifest depressive symptoms in patients with end-stage renal disease were associated with significantly higher 1-year all-cause mortality (26% vs 8%; HR 3.3; 95% CI 1.2-9.6; P=0.02).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: